Semiannual Report — FY2026 H1
What ASKA Pharmaceutical Holdings Co.,Ltd. reported for the period from 2026-04-01 to 2027-03-31.
Filed 2026-11-09View the original on EDINET
How much it says
51Typical
What moved here
11named for the first time
Its own wording
34terms
Which filing this is
17/ 17newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
During the interim consolidated accounting period, revenue increased 1.1% year on year to ¥35,626 million, operating profit increased 3.5% to ¥2,740 million, and interim net income attributable to owners of the parent decreased 9.6% to ¥2,006 million. In terms of business developments, the filing states that the technology introduction agreement, which included an option for an oral testosterone product, and the sales agreement for Chiroblock tablet sales rights have ended.
Komori's summary of this document, not the document's own words.51Typical
How much this filing saysA weighted roll-up of 10 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 35 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
93
Very detailed
30
Thin
42
Thin
75
Very detailed
50
Typical
32
Thin
27
Almost nothing
78
Very detailed
75
Very detailed
10
Almost nothing
R&D spend44億円Money spent making new things.
Cash left over-7億円Cash from the business, less what went into equipment.
Spent on equipment20億円Plants, machines — things meant to last.
EmployeesNot disclosedThis document does not carry the figure.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.